JRJing-Li Ren

Jing-Li Ren

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jing-Li Ren has a total of 319 co-authors. Here are the top co-authors by number of shared publications:

  • Fu-You Zhou

    Anyang Tumor Hospital, Anyang, China

    4 shared publications
  • Wen-Bin Yue

    Henan Key Laboratory for Esophageal Cancer Research of The First Affiliated Hospital, Zhengzhou University, Zhengzhou, China

    4 shared publications
  • Xin Song

    Department of Pathology, Cancer Research Center, Basic Medical College, Xinxiang Medical University, Xinxiang, China

    4 shared publications
  • Xiu-Min Li

    Department of Pathology, Cancer Research Center, Basic Medical College, Xinxiang Medical University, Xinxiang, China

    4 shared publications
  • Xue-Ke Zhao

    Henan Key Laboratory for Esophageal Cancer Research of The First Affiliated Hospital, Zhengzhou University, Zhengzhou, China

    4 shared publications
  • Bin Liu

    Department of Gastroenterology, Beijing Tongren Hospital Affiliated to Capital Medical University, Beijing, China

    3 shared publications

Latest Publications

  • Open Access

    H2A Histone Family Member Z (H2AFZ) Serves as a Prognostic Biomarker in Lung Adenocarcinoma: Bioinformatic Analysis and Experimental Validation

    by Zongkuo Li, Menglong Hu, Jinhuan Qiu, Junkai Feng, Ruizhen Zhang, Huifang Wu, Guiming Hu, Jingli Ren

    H2A Histone Family Member Z (H2AFZ) Serves as a Prognostic Biomarker in Lung Adenocarcinoma: Bioinformatic Analysis and Experimental Validation - Article abstract #933447


  • Open Access

    Case Report: A Case Report of a Histological Transformation of ALK-Rearranged Adenocarcinoma With High Expression of PD-L1 to Squamous Cell Carcinoma After Treatment With Alectinib

    by Yan Zhang, Yaping Qin, Hongen Xu, Qihui Yao, Yalan Gao, Yushu Feng, Jingli Ren

    We report an anaplastic lymphoma kinase (ALK)-positive patient shows a poor response to the ALK inhibitor alectinib due to the high expression of programmed death-ligand 1 (PD-L1). After treatment with alectinib, the pathological form changed from adenocarcinoma into squamous cell carcinoma without novel genetic changes. This case may reveal a direct relationship between ALK mutation and a high level of PD-L1 expression.


  • Open Access

    CKS2 (CDC28 protein kinase regulatory subunit 2) is a prognostic biomarker in lower grade glioma: a study based on bioinformatic analysis and immunohistochemistry

    by Menglong Hu, Zongkuo Li, Jinhuan Qiu, Ruizhen Zhang, Junkai Feng, Guiming Hu, Jingli Ren

    Gliomas account for the highest cases of primary brain malignancies. Whereas previous studies have demonstrated the roles of CDC28 Protein Kinase Regulatory Subunit 2 (CKS2) in various cancer types, its functions in lower grade gliomas (LGGs) remain elusive. This study aimed to profile the expression and functions of CKS2 in LGG. Multiple online databases such as The Cancer Genome Atlas (TCGA), the Chinese Glioma Genome Atlas (CGGA), Gene Expression Profiling Interactive Analysis 2nd edition (GEPIA2), Tumor Immune Estimation Resource 2nd edition (TIMER2.0) as well as Gene Expression Omnibus (GEO) were used in this study. Immunohistochemistry (IHC) was performed to evaluate CKS2 protein expression. Our data demonstrated upregulation of CKS2 in LGG tissues at both mRNA and protein level, especially in grade III gliomas. Similarly, there was increased expression of CKS2 in isocitrate dehydrogenase 1 (IDH1) wildtype gliomas. In addition, increased DNA copy number and DNA hypomethylation might be associated with the upregulation of the CKS2 in LGG. Using the Kaplan–Meier survival analysis and the Cox regression analysis, CKS2 was shown to be independently associated with poor prognosis of LGG patients. Receiver operating characteristic (ROC) analysis revealed that CKS2 could effectively predict the 1-, 3- and 5-year survival rates of LGG patients. Enrichment analyses revealed that CKS2 was mainly involved in the regulation of the cell cycle in LGG. Taken together, our study demonstrated that CKS2 might be a candidate prognostic biomarker for LGG and could predict the survival rates of LGG patients. Abbreviations: LGG: lower grade glioma; CKS2: CDC28 protein kinase regulatory subunit 2; TCGA: The Cancer Genome Atlas; CGGA: the Chinese Glioma Genome Atlas; GEO: Gene Expression Omnibus; GEPIA: Gene Expression Profiling Interactive Analysis; TIMER: Tumor Immune Estimation Resource; IHC: immunohistochemistry; qRT-PCR: quantitative real-time polymerase chain reaction; PBS: phosphate buffered saline; DAB: diaminobenzidine tetrachloride; OS: overall survival; CAN: copy number alteration; IDH: Isocitrate dehydrogenase; GSEA: Gene Set Enrichment Analysis; DEG: differentially expressed gene; KEGG: Kyoto encyclopedia of genes and genomes; GO: Gene ontology; BP: biological process; CC: cellular component; MF: molecular function; NES: normalized enrichment score; NOM: nominal; FDR: false discovery rate


  • Optimised architecture-based grading system as an independent prognostic factor in resected lung adenocarcinoma

    by Jin Huan Qiu, Gui Ming Hu, Rui Zhen Zhang, Menglong Hu, Zongkuo Li, Yan Zhang, Hui Fang Wu, Wen Jing Fu, Min Zhang, Yi Kun Feng, et al.

    Aims: Considering morphological heterogeneity of lung adenocarcinoma (LUAD) and no objective prognostic grading system existing currently, we aim to establish an ‘optimised architecture-based grading system’ (OAGS) to predict prognosis for resected LUAD. Methods: A multicentral study involving three independent cohorts of LUAD was conducted. Predictive ability of the OAGS for recurrence-free probability (RFP) and overall survival (OS) was assessed in training cohort (n=228) by the area under the receiver operating characteristic curve (AUC), Harrell’s concordance index ( C -index) and Kaplan-Meier survival analyses, which was validated in testing (n=135) and validation (n=226) cohorts. Results: The OAGS consists of: grade 1 for lepidic, papillary or acinar predominant tumour with no or less than 5% of high-grade patterns (cribriform, solid and or micropapillary), grade 2 for lepidic, papillary or acinar predominant tumour with 5% or more of high-grade patterns, and grade 3 for cribriform, solid or micropapillary predominant tumour. In all stages, the OAGS outperformed the pattern-dominant grading system and IASLC grading system for predicting RFP (C-index, 0.649; AUC, 0.742) and OS (C-index, 0.685; AUC, 0.754). Multivariate analysis identified it as an independent predictor of both (RFP, p<0.001; OS, p<0.001). Furthermore, in pT1-2aN0M0 subgroup, the OAGS maintained its ability to predict recurrence (C-index, 0.699; AUC, 0.769) and stratified patients into different risk groups of RFP (p<0.001). These results were confirmed in testing and validation cohorts. Conclusions: The OAGS is an independent prognostic factor and shows a robust ability to predict prognosis for resected LUAD.


  • Clinical significance of the cribriform pattern in invasive adenocarcinoma of the lung

    by Ruizhen Zhang, Guiming Hu, Jinhuan Qiu, Huifang Wu, Wenjing Fu, Yikun Feng, Min Zhang, Chen Chen, Jianping Sun, Yan Zhang, et al.

    Purpose According to the WHO, the cribriform pattern is a subtype of acinar (Aci) predominance in invasive adenocarcinoma (ADC) of the lung. Recently, several studies have demonstrated poor prognosis in patients with cribriform predominance. This study was performed to examine the correlations of cribriform pattern with the clinicopathology, molecular features and prognosis in patients with invasive ADC. Methods Histological subtypes were evaluated in 279 patients who underwent complete resection for invasive ADC. Patients of the Aci-predominant subtype were divided into two subgroups according to the percentage of cribriform cancer (≥5% vs Results A cribriform pattern was found in 111 (39.8%) cases and ranged from 5 % to 100 % of the total tumour volume (mean±SEM, 30%±2%). Of 117 patients with Aci predominance, 79 showed the cribriform pattern, while the remaining 38 did not. The cribriform pattern was associated with aggressive pathological behaviour, including advanced stages of cancer, nuclear atypia, mitoses, lymph node invasion, metastasis and larger tumour size. The subgroup with cribriform cancer (≥5%) had significantly poorer OS and DFS compared with the cribriform-negative (Conclusion The cribriform pattern is associated with aggressive pathological behaviour and is an independent poor prognostic indicator in patients with Aci-predominant ADC of the lung.


  • Open Access

    Cellular and clinicopathological features of the IL-33/ST2 axis in human esophageal squamous cell carcinomas

    by Guanglin Cui, Jingli Ren, Gang Xu, Zhenfeng Li, Wei Zheng, Aping Yuan

    Emerging evidence has suggested that interleukin (IL)-33 and its primary functional receptor ST2 are involved in the pathogenesis of tumorigenesis. Using immunohistochemistry (IHC) and double immunofluorescence staining, we characterized the cellular and clinicopathological features of the IL-33/ST2 axis in different compartments in human esophageal squamous cell carcinoma (ESCC) surgical specimens. IHC data revealed an increased expression of IL-33-immunoreactivity (IR) and ST2-IR located in both ESCC cells and tumor stromal cells; which were associated with advanced clinicopathological features such as TNM stages and node involvement. However, the Kaplan–Meier analysis showed that densities of neither IL-33 positive nor ST2 positive cells in both the ESCC mass and stroma were associated with the overall survival rate in patients with ESCC. Double immunofluorescence staining for cellular feature analysis demonstrated that these IL-33 positive and ST2 positive cells in ESCCs were with a high proliferation rate, and IL-33-IR was frequently co-expressed with ST2-IR in both ESCC and stromal cells. Significant altered cellular features of the IL-33/ST2 axis in ESCCs were associated with advanced clinicopathological variables. The data suggest that the IL-33/ST2 axis might be involved in the progression of human ESCCs.


  • No significant association between PIK3CA mutation and survival of esophageal squamous cell carcinoma: A meta-analysis

    by Xiao-Qing Ge, Yan-Zheng Yang, Sha-Sha Li, Lu Hou, Jing-Li Ren, Kun-Peng Yang, Xian-En Fa

    The prognostic value of phosphatidylinositol-4, 5-bisphosphate 3-kinase, catalytic subunit alpha (PIK3CA) in patients with esophageal squamous cell carcinoma (ESCC) is controversial. We aimed to investigate the prognostic significance of PIK3CA mutation in patients with ESCC. EMBASE, PubMed, and Web of Science databases were systematically searched from inception through Oct. 3, 2016. The hazard ratios (HRs) and 95% confidence intervals (CI) were calculated using a random effects model for overall survival (OS) and disease-free survival (DFS). Seven studies enrolling 1505 patients were eligible for inclusion of the current meta-analysis. Results revealed that PIK3CA mutation was not significantly associated with OS (HR: 0.90, 95% CI: 0.63–1.30, P=0.591), with a significant heterogeneity (I2=65.7%, P=0.012). Additionally, subgroup analyses were further conducted according to various variables, such as types of specimen, the sample size, technique and statistical methodology. All results suggested that no significant relationship was found between PIK3CA mutation and OS in patients with ESCC. For DFS, there was no significant association between PIK3CA mutation and DFS in patients with ESCC (HR: 1.00, 95% CI=0.47–2.11, P=0.993, I2=73.7%). Publication bias was not present and the results of sensitivity analysis were very stable in the current meta-analysis. Our findings suggest that PIK3CA mutation has no significant effects on OS and DFS in ESCC patients. More well-designed prospective studies with better methodology for PIK3CA assessment are required to clarify the prognostic significance of PIK3CA mutation in ESCC patients.


  • C-Met as a potential novel prognostic marker in squamous cell carcinoma and adenocarcinoma of esophagus: evidence from a meta-analysis

    by Jing L. Ren, Hui F. Wu, Wen J. Wang, Gui M. Hu, Bin Gu, Min Zhang, Yu X. Wang

    Article: C-Met as a potential novel prognostic marker in squamous cell carcinoma and adenocarcinoma of esophagus: evidence from a meta-analysis - Panminerva Medica 2017 March;59(1):97-106 - Minerva Medica - Journals


    • 1 October 2016
      • Vol. 107  (5) , 328-341

    Role of human epidermal growth factor receptor 2 as a prognostic factor for survival in esophageal carcinoma: evidence from 2872 subjects

    by Wen J. Wang, Min J. Wu, Jia Chang, Peng Xie, Zhi Q. Lu, Jing L. Ren

    INTRODUCTION: The prognostic value of human epidermal growth factor receptor 2 (HER2) in esophageal carcinoma (EC) remains controversial. Our study aims to clarify the correlation between HER2 overexpression and survival in patients with EC. EVIDENCE ACQUISITION: A comprehensive search of EMBASE, PubMed, and Web of Science was performed from inception to April 17, 2016 to search published literature regarding the potential association between HER2 overexpression and prognosis in EC patients. A pooled hazard ratio (HR) with 95% confidence intervals (CIs) was applied to evaluate the effect of HER2 overexpression for overall survival (OS) and disease-free survival (DFS). EVIDENCE SYNTHESIS: Eighteen studies were identified (2872 patients). HER2 overexpression was significantly associated with poor OS (HR=1.43, 95% CI: 1.11-1.85, P=0.006). This effect was observed both ESCC (HR=1.48, 95% CI: 1.04-2.11, P=0.031) and in EAC (HR=1.62, 95% CI: 1.07-2.46, P=0.023). Besides, similar striking correlations were demonstrated for DFS (HR=2.02, 95% CI: 1.55-2.65, P<0.0001), and also discovered in ESCC (HR=2.45, 95% CI: 1.26-4.76, P=0.008) as well as EAC (HR=1.95, 95% CI: 1.45-2.62, P<0.0001). Additionally, the pooled HR of sensitivity analysis ranged from 1.37 (95% CI: 1.06-1.76) to 1.52 (95% CI: 1.17-1.97) for OS, and 1.94 (95% CI: 1.46-2.58) to 2.15 (95% CI: 1.55-2.99) for DFS, respectively. No single article significantly influenced the pooled HR, and there were no obvious publication biases. CONCLUSIONS: These results provide further evidence that HER2 overexpression is significantly associated with reduced survival in EC. HER2 may be used as a prognostic biomarker for EC patients.


  • Open Access

    P16INK4a is not a Reliable Screening Marker of HPV Infection in Esophageal Squamous Cell Carcinoma: Evidence from a Meta-Analysis

    by Wen-Jie Wang, Min-Jie Wu, Jing-Li Ren, Peng Xie, Jia Chang, Gui-Ming Hu, Hui-Fang Wu

    Background: The role of p16INK4a as a surrogate marker for screening human papillomavirus (HPV) in esophageal squamous cell carcinoma (ESCC) remains controversial. Methods: A comprehensive search of EMBASE, PubMed, China National Knowledge Infrastructure and China Biology Medicine was performed from inception to December 27, 2015. A random-effects model was applied to the pooled odds ratios (ORs) with 95% confidence intervals (CIs). Results: Ten studies were identified (985 cases). The pooled results showed no significant relationship between p16INK4a expression and HPV infection in ESCC based on overall HPV types (OR: 1.79, 95% CI: 0.69-4.66, p = 0.235). Subgroup analysis by HPV detection method showed no statistical significance in either the polymerase chain reaction (PCR) (OR: 1.65, 95% CI: 0.83-3.30, p = 0.154) or in situ hybridization (ISH) group (OR: 2.58, 95% CI: 0.03-268.14, p = 0.689). The pooled OR of the sensitivity analysis ranged from 1.27 (95% CI: 0.58-2.84) to 2.32 (95% CI: 0.95-5.64). Of these studies, 6 involved only high-risk human papillomavirus types (HR-HPV), HPV16 or HPV18. However, similar observations were made for HR-HPV (OR = 1.31, 95% CI: 0.26-6.59, p = 0.741). Subgroup analysis again showed no statistical significance in the PCR group (OR: 0.95, 95% CI: 0.25-3.64, p = 0.940) and ISH group (OR: 2.58, 95% CI: 0.03-268.14, p = 0.689). Sensitivity analysis showed that the pooled OR ranged from 0.69 (95% CI: 0.21-2.22) to 1.89 (95% CI: 0.33-10.86). Conclusions: p16INK4a is not a reliable screening marker of HPV infection in ESCC. Further multicenter, large-sample and well-matched prospective studies are still required to illuminate the possible etiological roles of HPV in ESCC.